Predictive health company Potrero Medical today filed an SEC Form D/A disclosing the sale of nearly $5.5 million in equity.
The amendment the equity offering which made its first sale on June 28. At that time, the offering was for a total of $15 million and, in July, the company announced that it sold $11.7 million of that offering.
Today’s amendment revealed that the company sold about $5.5 million in addition to the July sale and the total offering amount sits at $20 million, with $2.8 million left to be sold. Potrero does not expect the offering to last more than a year.
The July sale included 20 investors and the amendment showed that there are now 26 investors involved in the offering. Potrero did not disclose the intended use of proceeds.
The Hayward, Calif.-based company’s Accuryn system is designed to use urinary catheters as diagnostic tools. The device provides real-time measurements of intra-abdominal pressure, urine output and core body temperature and can be integrated into hospital EMR systems, according to Potrero.
The company closed a $26.6 million Series C funding round in July 2018 to help support commercialization of Accuryn.